本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

伊克力西斯

39.25
+0.04000.10%
盤後39.250.00000.00%19:25 EDT
成交量:218.85萬
成交額:8,547.90萬
市值:105.66億
市盈率:18.90
高:39.60
開:39.33
低:38.62
收:39.21
52周最高:49.62
52周最低:27.86
股本:2.69億
流通股本:2.32億
量比:0.91
換手率:0.94%
股息:- -
股息率:- -
每股收益(TTM):2.08
每股收益(LYR):1.80
淨資產收益率:29.00%
總資產收益率:17.24%
市淨率:5.20
市盈率(LYR):21.84

資料載入中...

公司資料

公司名字:
伊克力西斯
交易所:
NASDAQ
成立時間:
1994
員工人數:
1147
公司地址:
1851 Harbor Bay Parkway,Alameda,California,United States
郵編:
94502
電話:
傳真:
650 837 8300
簡介:
Exelixis, Inc.是一家生物科技公司,致力於研發癌症小分子治療。公司於1994年11月在特拉華州註冊為Exelixis製藥股份有限公司,並於2000年2月改為Exelixis股份有限公司。公司的資源、研發、生產專註於COMETRIQ(卡博替尼膠囊,公司全資的多靶點受體酪氨酸激酶抑製劑)。公司目標是將COMETRIQ發展成一項主要的特許腫瘤經營產品,認為COMETRIQ治療惡化、轉移的MTC的批准給實現該目標、樹立商業地位提供了一個機會。

董事

名稱
職位
Michael M. Morrissey
President and Chief Executive Officer, Director
David E. Johnson
Independent Director
George Poste
Independent Director
Jack L. Wyszomierski
Independent Director
Julie A. Smith
Independent Director
Maria C. Freire
Independent Director
Mary C. Beckerle
Independent Director
Robert L. Oliver
Independent Director
S. Gail Eckhardt
Independent Director
Stelios Papadopoulos
Independent Chair of the Board
Tomas J. Heyman
Independent Director

股東

名稱
職位
Michael M. Morrissey
President and Chief Executive Officer, Director
Christopher J. Senner
Executive Vice President and Chief Financial Officer
Dana T. Aftab
Executive Vice President, Discovery and Translational Research and Chief Scientific Officer, Executive Vice President, Research and Development
Jeffrey J. Hessekiel
Executive Vice President and General Counsel
Patrick J. Haley
Executive Vice President, Commercial